Classifications

• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
  • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
  • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
  • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
  • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
  • Y10S530/813—Carrier is a saccharide
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
  • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
  • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
  • Y10S530/815—Carrier is a synthetic polymer
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
  • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
  • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
  • Y10S530/815—Carrier is a synthetic polymer
  • Y10S530/817—Entrapped within the carrier, e.g. gel, hollow fibre

Definitions

• cyclodextnns as cyclic oligosaccharides .
• the a , ⁇ , and ⁇ -cyclodextnns which consist of six, seven, and eight glucose units, respectively, are the most common natural cyclodextnns .
• Cyclodextnns have been used as inclusion complexes by complexmg with a guest compound or molecule as a host compound or molecule. Such inclusion complexes have been used to mask the bitter taste or unpleasant odor of a guest compound, to solubilize a hardly soluble guest compound, to enlarge the stability of a guest compound against heat, light, or air, to stabilize emulsions, or as a sustained release preparation using a hydrophobic alkylated cyclodextrin. See U.S. Patent No. 4,869.904. However, no one has attempted to make carboxyacylated cyclodextnns, or used such cyclodextrin derivatives to form ionic sustained release compositions.
• the present invention features a cyclodextrin derivative, wherein at least 60 (e.g., between 75 and 100) percent of the free hydroxy groups of the cyclodextrin are acylated with acyl groups where at least one of the acyl groups comprises a free carboxylic group.
• cyclodextrin is a cyclic oligosaccharide .
• Examples of cyclodextnns include a- cyclodext ⁇ n, 3-cyclodextrm, or ⁇ -cyclodext ⁇ n.
• the acyl groups are selected from COE ⁇ where E ⁇ is selected from the group consisting of C 2 32 carboxy alkyl , C 3 33 carboxy alkenyl, C 737 carboxyaryl , C 838 carboxyaryl alkyl , and C 939 carboxyaryl alkenyl, and COE 2 , where E 2 is selected from the group consisting of C x 30 alkyl, C 230 alkenyl, C 636 aryl , C 737 arylalkyl, and C 8 _ 38 arylalkenyl, wherein at least one of the acyl group is .
• the invention features a copolymer comprising the cyclodextrin derivative described above, wherein the cyclodextrin derivative comprises at least one free hydroxy group which is acylated with a polyester comprising hydroxy acid monomers.
• the copolymer has an average molecular weight of between 500 - 40,000 daltons (e.g., 500 - 10,000).
• the polyester comprises hydroxy acid monomers selected from the group consisting of lactic acid, glycolic acid, hydroxy caprolic acid, or any optically active isomer thereof.
• polyesters can be manufactured by reacting said cyclodextrin derivative with lactide, glycolide, caprolactone, p-dioxanone, trimethyl carbonate, or any optically active isomer thereof.
• the invention features a composition comprising the cyclodextrin derivative described above and a drug, the drug comprising at least one effective ionogenic amine, wherein at least 50 percent, by weight, of the polypeptide present in the composition is ionically bonded to the cyclodextrin derivative.
• the composition comprises between 1 and 30 (e.g., between 10 and 20) percent, by weight, of the drug.
• the drug is a polypeptide.
• the polypeptide comprises between 4 and 200 amino acids (e.g., between 4 and 50 ammo acids) .
• the polypeptide include somatostatm, bombesm, calcitonm, amylm, parathyroid hormone, parathyroid hormone related protein, gast ⁇ n releasing peptide, lutemizmg hormone releasing hormone, growth hormone, growth hormone releasing factor, terferons, erythropoietm, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, pituitary adenylate cyclase activating polypeptide, vasoactive intestinal peptide, thyrotropm releasing hormone, corticotrop releasing hormone, Acetyl-Ser-Asp-Lys-Pro, argmme vasopressm, angiotensm, and any fragments, agonists, or antagonists thereof.
• the invention features a composition comprising the copolymer described above and a drug, the drug comprising at least one effective lonogenic am e, wherein at least 50 percent, by weight, of the polypeptide present in the composition is lonically bonded to the cyclodextrin derivative.
• the composition comprises between 1 and 30
• the drug is a polypeptide .
• lower alkyl is intended to include both branched and straigh -chain saturated aliphatic hydrocarbon groups.
• Examples of lower alkyl groups include methyl, ethyl, propyl , isopropyl, butyl, t-butyl, isobutyl, sec-butyl, and the like.
• Lower alkenyl include those branched and straight chain aliphatic hydrocarbon groups having one or several double bonds.
• alkenyl groups include vinyl, allyl, isopropenyl, butenyl, pentenyl, hexenyl , 1-propenyl, 2- butenyl , 2 -methyl -2 -butenyl , isoprenyl, and the like. All alkyl, alkenyl, and alkynyl groups are noncyclic.
• aryl is intended to include any stable monocyclic, bicyclic, or t ⁇ cyclic carbon rmg(s) of up to 7 members m each ring, wherein at least one ring is aromatic.
• aryl groups include phenyl, naphthyl , anthracenyl, biphenyl, tetrahydronaphthyl, mdanyl, phenanthreynl, and the like.
• carboxy is meant to include the recited chemical group (e.g., alkyl, alkenyl, aryl, arylalkyl, arylalkenyl) substituted with 1 to 3 carboxy groups.
• Cyclodextrin (Amaizo, American Maize Products Corp. Hammond, IN) was dried at 90 °C under reduced pressure (0.1 mm Hg) to a constant weight. Dried cyclodextrin (CD) was then transferred to a reaction flask equipped for stirring. After purging with argon, the CD was heated at 50°C for 30 mm. at 0.1 mm Hg, cooled to 25 °C, and repurged with dry argon. Calculated amount of the acylating reagent, as a liquid anhydride (except in ADC No.
• the resulting precipitate was filtered, rinsed several times with cold water, and air dried. The product was then isolated and dried until constant weight under vacuum, first at 25°C and then 50°C. The product was characterized for equivalent weight, as reported in Table I, by measuring titratable carboxylic acid functionally using benzyl alcohol solution of the product and potassium hydroxide in benzyl alcohol with bromophenol red as an indicator.
• CD is ⁇ -Cyclodextrin
• A is Acetic Anhydride
• P is Propionic Anhydride
• B is Butyric Anhydride
• S is Succinic Anhydride
• G Gluta ⁇ c Anhydride
• Example 2 Grafting Acylated Cyclodextrin (G-ACD) with Lactones
• G-ACD acylated Cyclodextrin derivative
• ACD acylated cyclodextrin derivative
• lactone or mixture of lactones a catalytic amount (i.e., ⁇ 0.2 percent by weight) of stannous octoate
• a catalytic amount i.e., ⁇ 0.2 percent by weight
• the amount of ACD and lactones used are described m Table II.
• the mixture was then heated under vacuum at about 45°C for 30 min. , cooled to room temperature, and then purged with dry argon.
• the reactants were then heated while stirring as described Table II.
• G is glycolide
• L is D,L-Lactide
• CL is e -Caprolactone
• acylated ⁇ - cyclodextrin (ACD) was dissolved in a minimum volume of acetone (from 5-15 weight/volume percent) and filtered through a micro-syringe with 0.45 ⁇ m porous filter. The filtrate was cooled and a IN sodium hydroxide aqueous solution was added to neutralize carboxylic groups in the ACD.
• the weight of the dried composition was determined, and the composition was characterized for percent content of peptide, as measured by elemental analysis of the percent of nitrogen present in the composition (Quantitative Technologies, Inc., Whitehouse, NJ) , as reported in Table III.
• the particulate product was reduced in size by grinding to achieve an average particle size of about 100 ⁇ before storage under reduced pressure.
• G-ACD grafted ACD
• both the ungrafted composition U-CON- 19 and the grafted composition U-CON- 16 released the drug LanreotideTM over a period of at least 22 days.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Nanotechnology (AREA)
• Pharmacology & Pharmacy (AREA)
• Biochemistry (AREA)
• Materials Engineering (AREA)
• Polymers & Plastics (AREA)
• Biophysics (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Medical Informatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Crystallography & Structural Chemistry (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=24978025

Family Applications (1)

Country Status (13)

Cited By (3)

Families Citing this family (35)

Citations (3)

Family Cites Families (16)

• 1996
  • 1996-11-01 US US08/740,778 patent/US5916883A/en not_active Expired - Lifetime
• 1997
  • 1997-10-06 NZ NZ335387A patent/NZ335387A/en unknown
  • 1997-10-06 DE DE69713369T patent/DE69713369T2/de not_active Expired - Fee Related
  • 1997-10-06 PT PT97910005T patent/PT935613E/pt unknown
  • 1997-10-06 ES ES97910005T patent/ES2176705T3/es not_active Expired - Lifetime
  • 1997-10-06 WO PCT/US1997/018105 patent/WO1998020044A1/en not_active Ceased
  • 1997-10-06 AU AU47483/97A patent/AU728398B2/en not_active Ceased
  • 1997-10-06 EP EP97910005A patent/EP0935613B1/en not_active Expired - Lifetime
  • 1997-10-06 CA CA002269519A patent/CA2269519C/en not_active Expired - Fee Related
  • 1997-10-06 AT AT97910005T patent/ATE219109T1/de not_active IP Right Cessation
  • 1997-10-06 IL IL12965297A patent/IL129652A0/xx unknown
  • 1997-10-06 JP JP52139498A patent/JP2001503802A/ja not_active Ceased
  • 1997-10-06 DK DK97910005T patent/DK0935613T3/da active
• 1999
  • 1999-04-08 US US09/288,471 patent/US6204256B1/en not_active Expired - Lifetime

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events